文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

嵌合抗原受体T细胞（CAR-T）疗法后出现继发性恶性肿瘤报告后的未解问题。

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.

作者信息

Levine Bruce L, Pasquini Marcelo C, Connolly John E, Porter David L, Gustafson Michael P, Boelens Jaap J, Horwitz Edwin M, Grupp Stephan A, Maus Marcela V, Locke Frederick L, Ciceri Fabio, Ruggeri Annalisa, Snowden John, Heslop Helen E, Mackall Crystal L, June Carl H, Sureda Anna M, Perales Miguel-Angel

机构信息

Center for Cellular Immunotherapies and Department of Pathology and Laboratory Medicine, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA.

Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

出版信息

Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.

DOI:10.1038/s41591-023-02767-w
PMID:38195751
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11688691/
Abstract

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

摘要

嵌合抗原受体T细胞（CAR-T）疗法后T细胞恶性肿瘤的报告应予以调查，但随访研究的现有数据表明，与其他癌症治疗方法相比，其风险较低。

相似文献

[1]
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.

Nat Med. 2024-2

[2]
CAR-T cell therapy for patients with hematological malignancies. A systematic review.

Eur J Haematol. 2022-12

[3]
Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience.

Haematologica. 2023-8-1

[4]
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

Transplant Cell Ther. 2022-6

[5]
State of the art in CAR T cell therapy for CD19+ B cell malignancies.

J Clin Invest. 2020-4-1

[6]
Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.

Cancer Treat Res Commun. 2022

[7]
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.

J Clin Invest. 2021-1-19

[8]
Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety.

Best Pract Res Clin Haematol. 2018-6

[9]
Incidence and prophylaxis of herpes zoster in relapsed or refractory B-cell lymphoma patients after CD19-specific CAR-T cell therapy.

Leuk Lymphoma. 2022-4

[10]
Bibliometric analysis of research trends and active research areas in chimeric antigen receptor T cell therapy for hematologic malignancies.

Int J Clin Pharm. 2024-2

引用本文的文献

[1]
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.

Bone Marrow Transplant. 2025-9-9

[2]
Targeting the roots of myeloid malignancies with T cell receptors.

Nat Rev Cancer. 2025-8-21

[3]
Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapies.

J Transl Med. 2025-8-19

[4]
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.

Virchows Arch. 2025-8-13

[5]
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy.

Nat Commun. 2025-8-12

[6]
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.

NPJ Digit Med. 2025-8-1

[7]
Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies.

Front Immunol. 2025-7-17

[8]
Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions.

Front Immunol. 2025-7-3

[9]
Noncanonical and mortality-defining toxicities of CAR T cell therapy.

Nat Med. 2025-7-16

[10]
In vitro HIV DNA integration in STAT3 drives T cell persistence-A model of HIV-associated T cell lymphoma.

PLoS Pathog. 2025-7-8

本文引用的文献

[1]
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease.

Nat Med. 2023-12

[2]
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.

Mol Ther. 2023-3-1

[3]
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.

Blood Adv. 2022-9-13

[4]
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.

Blood Adv. 2023-2-28

[5]
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.

Blood. 2022-7-7

[6]
Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells.

Blood. 2021-10-21

[7]
The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.

Blood. 2021-9-2

[8]
T-cell lymphoma secondary to checkpoint inhibitor therapy.

J Immunother Cancer. 2020-2

[9]
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

N Engl J Med. 2015-12-24

[10]
Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.

Mol Ther. 2013-4-23

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索